Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.897,81
-0,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immuron Ltd (IMRN) Immuron Ltd (IMRN) Notizie

Immuron Ltd

IMRN
2,52
-0,02 (-0,79%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/5/202412:00GLOBEImmuron Director Resignation
15/4/202412:00GLOBEImmuron to host Live Virtual Event
10/4/202412:00GLOBEImmuron Travelan® sales continued strong growth
07/3/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202412:00GLOBEImmuron Announces Positive Results Support Travelan®..
28/2/202414:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202412:00GLOBEImmuron Presentation Australian Biologics Festival 2024
13/2/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/2/202412:00GLOBEImmuron achieves record Travelan® sales
08/2/202412:00GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
16/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202412:00GLOBEImmuron achieves record half yearly Travelan® sales
22/12/202313:21EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202312:00GLOBEImmuron Clinical Trials Update
04/12/202312:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202312:00GLOBEImmuron Announces First Patients Enrolled in Campylobacter..
28/11/202312:33GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
28/11/202312:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202313:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202300:00GLOBEImmuron CEO Steven Lydeamore Investor Webinar Presentation
13/11/202314:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202312:21GLOBEImmuron CEO Steven Lydeamore presented at AusBioInvest
23/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202312:00GLOBEImmuron Announces Travelan® Clinical Study Cohort 2..
11/10/202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202312:00GLOBEImmuron achieves record quarterly Travelan® sales
28/9/202314:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202312:18EDGAR2Form 20-F - Annual and transition report of foreign private..
13/9/202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202312:00GLOBEImmuron achieves record monthly Travelan® sales
11/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202312:00GLOBEImmuron CEO, Steven Lydeamore to present at H.C. Wainwright
30/8/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202312:00GLOBEImmuron to present at the Military Health System Research..
09/8/202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/7/202312:00GLOBEImmuron Announces First Patients Enrolled in Travelan®..
25/7/202303:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202312:00GLOBEImmuron CEO, Steven Lydeamore to present at Bioshares
11/7/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202312:00GLOBEImmuron Business Update - Ateria Health launches Juvia™ in..
05/7/202312:00GLOBEImmuron FY23 Sales increase 136% on FY22 Sales
30/6/202312:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/6/202312:00GLOBEImmuron Chairman Transition
22/6/202312:00GLOBEImmuron Business Update: Letter to Shareholders
Apertura: 2,62 Min: 2,4815 Max: 2,62
Chiusura: 2,54

La tua Cronologia

NASDAQ
IMRN
Immuron
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network